PL3068869T3 - Kompozycje do hamowania wytwarzania inhibitorów przeciwko czynnikowi viii u pacjentów z hemofilią a - Google Patents
Kompozycje do hamowania wytwarzania inhibitorów przeciwko czynnikowi viii u pacjentów z hemofilią aInfo
- Publication number
- PL3068869T3 PL3068869T3 PL14862042T PL14862042T PL3068869T3 PL 3068869 T3 PL3068869 T3 PL 3068869T3 PL 14862042 T PL14862042 T PL 14862042T PL 14862042 T PL14862042 T PL 14862042T PL 3068869 T3 PL3068869 T3 PL 3068869T3
- Authority
- PL
- Poland
- Prior art keywords
- hemophilia
- suppression
- patients
- compositions
- factor viii
- Prior art date
Links
- 208000031220 Hemophilia Diseases 0.000 title 1
- 208000009292 Hemophilia A Diseases 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 229960000301 factor viii Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000001629 suppression Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
- C12N15/8214—Plastid transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361905069P | 2013-11-15 | 2013-11-15 | |
| US201361905071P | 2013-11-15 | 2013-11-15 | |
| EP14862042.0A EP3068869B1 (en) | 2013-11-15 | 2014-11-17 | Compositions for suppression of inhibitor formation against factor viii in hemophilia a patients |
| PCT/US2014/065994 WO2015073988A1 (en) | 2013-11-15 | 2014-11-17 | Compositions and methods for suppression of inhibitor formation against factor viii in hemophilia a patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3068869T3 true PL3068869T3 (pl) | 2021-03-08 |
Family
ID=53058150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14862042T PL3068869T3 (pl) | 2013-11-15 | 2014-11-17 | Kompozycje do hamowania wytwarzania inhibitorów przeciwko czynnikowi viii u pacjentów z hemofilią a |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10233216B2 (pl) |
| EP (2) | EP3068869B1 (pl) |
| AU (1) | AU2014348289B2 (pl) |
| CA (1) | CA2967269C (pl) |
| CY (1) | CY1123792T1 (pl) |
| DK (1) | DK3068869T3 (pl) |
| ES (1) | ES2821882T3 (pl) |
| HR (1) | HRP20201680T1 (pl) |
| HU (1) | HUE050869T2 (pl) |
| LT (1) | LT3068869T (pl) |
| PL (1) | PL3068869T3 (pl) |
| PT (1) | PT3068869T (pl) |
| RS (1) | RS60929B1 (pl) |
| SI (1) | SI3068869T1 (pl) |
| WO (1) | WO2015073988A1 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2881463A1 (en) * | 2013-12-09 | 2015-06-10 | DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH | Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders |
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| JP2019503341A (ja) * | 2015-11-16 | 2019-02-07 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 植物細胞に生物学的に封入された、治療用タンパク質の、疾患の治療のための関心のある細胞型への標的化された送達 |
| WO2017165320A1 (en) * | 2016-03-20 | 2017-09-28 | The Trustees Of The University Of Pennsylvania | Codon optimization and ribosome profiling for increasing transgene expression in chloroplasts of higher plants |
| GB201813528D0 (en) | 2018-08-20 | 2018-10-03 | Ucl Business Plc | Factor IX encoding nucleotides |
| US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110179530A1 (en) | 2001-01-23 | 2011-07-21 | University Of Central Florida Research Foundation, Inc. | Pharmaceutical Proteins, Human Therapeutics, Human Serum Albumin Insulin, Native Cholera Toxin B Subunit on Transgenic Plastids |
| EP2080803B1 (en) | 2000-03-01 | 2011-05-25 | Auburn University | Plastid transformation vectors for expressing proinsulin fused to the cholera toxin B-subunit in plants |
| AU2001245359A1 (en) | 2000-03-02 | 2001-09-12 | Auburn University | Marker free transgenic plants: engineering the chloroplast genome without the use of antibiotic selection |
| AU2002358292B2 (en) | 2001-12-26 | 2008-12-18 | University Of Central Florida | Expression of protective antigens in transgenic chloroplasts and the production of improved vaccines |
| AU2003253781A1 (en) | 2002-07-03 | 2004-01-23 | University Of Central Florida | Expression of human interferon in transgenic chloroplasts |
| EP1747294A2 (en) * | 2004-05-11 | 2007-01-31 | Wyeth a Corporation of the State of Delaware | Novel polynucleotides related to oligonucleotide arrays to monitor gene expression |
| GB0709803D0 (en) * | 2007-05-22 | 2007-07-04 | Ucl Business Plc | Predictive method |
| WO2011057243A2 (en) * | 2009-11-09 | 2011-05-12 | University Of Central Florida Research Foundation, Inc. | Administration of plant expressed oral tolerance agents |
| US8454957B2 (en) * | 2010-06-17 | 2013-06-04 | Stemnion, Inc. | Methods for treating coagulation disorders |
| US20130017997A1 (en) * | 2010-08-19 | 2013-01-17 | Amunix Operating Inc. | Factor VIII Compositions and Methods of Making and Using Same |
| EP2770991B9 (en) * | 2011-10-24 | 2017-01-25 | The Trustees Of The University Of Pennsylvania | Orally-administered plastid expressed cholera toxin b subunit-exendin 4 for use in the treatment of type 2 diabetes |
| SMT201800586T1 (it) * | 2012-01-12 | 2019-01-11 | Bioverativ Therapeutics Inc | Riduzione dell'immunogenicita' contro il fattore viii negli individui che si sottopongono alla terapia con fattore viii |
-
2014
- 2014-11-17 PL PL14862042T patent/PL3068869T3/pl unknown
- 2014-11-17 HR HRP20201680TT patent/HRP20201680T1/hr unknown
- 2014-11-17 EP EP14862042.0A patent/EP3068869B1/en active Active
- 2014-11-17 PT PT148620420T patent/PT3068869T/pt unknown
- 2014-11-17 LT LTEP14862042.0T patent/LT3068869T/lt unknown
- 2014-11-17 EP EP20185791.9A patent/EP3763381A1/en not_active Withdrawn
- 2014-11-17 HU HUE14862042A patent/HUE050869T2/hu unknown
- 2014-11-17 SI SI201431680T patent/SI3068869T1/sl unknown
- 2014-11-17 AU AU2014348289A patent/AU2014348289B2/en active Active
- 2014-11-17 CA CA2967269A patent/CA2967269C/en active Active
- 2014-11-17 US US15/037,045 patent/US10233216B2/en active Active
- 2014-11-17 WO PCT/US2014/065994 patent/WO2015073988A1/en not_active Ceased
- 2014-11-17 ES ES14862042T patent/ES2821882T3/es active Active
- 2014-11-17 DK DK14862042.0T patent/DK3068869T3/da active
- 2014-11-17 RS RS20201237A patent/RS60929B1/sr unknown
-
2019
- 2019-03-12 US US16/299,928 patent/US10556932B2/en active Active
-
2020
- 2020-02-11 US US16/787,778 patent/US20200270313A1/en not_active Abandoned
- 2020-10-22 CY CY20201101009T patent/CY1123792T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20200270313A1 (en) | 2020-08-27 |
| WO2015073988A1 (en) | 2015-05-21 |
| EP3763381A1 (en) | 2021-01-13 |
| HUE050869T2 (hu) | 2021-01-28 |
| RS60929B1 (sr) | 2020-11-30 |
| EP3068869A4 (en) | 2017-04-05 |
| CY1123792T1 (el) | 2022-03-24 |
| CA2967269C (en) | 2022-04-26 |
| US20190194265A1 (en) | 2019-06-27 |
| SI3068869T1 (sl) | 2020-11-30 |
| DK3068869T3 (da) | 2020-09-07 |
| EP3068869B1 (en) | 2020-07-22 |
| EP3068869A1 (en) | 2016-09-21 |
| HRP20201680T1 (hr) | 2021-03-19 |
| AU2014348289A1 (en) | 2016-06-16 |
| AU2014348289B2 (en) | 2020-11-26 |
| US10233216B2 (en) | 2019-03-19 |
| US20160289277A1 (en) | 2016-10-06 |
| ES2821882T3 (es) | 2021-04-28 |
| LT3068869T (lt) | 2020-10-26 |
| CA2967269A1 (en) | 2015-02-21 |
| PT3068869T (pt) | 2020-10-08 |
| US10556932B2 (en) | 2020-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274024A (en) | Oral preparations | |
| EP2948450A4 (en) | METALLOENZYMINHIBITORVERBINDUNGEN | |
| ZA201506487B (en) | Therapeutic compounds and compositions | |
| IL241078A0 (en) | Synergistic preparations | |
| EP2894981A4 (en) | METALLO ENZYME INHIBITOR COMPOUNDS | |
| PL2804858T3 (pl) | Związki - inhibitory metaloenzymu | |
| PL3079666T3 (pl) | Kompozycje farmaceutyczne zawierające fumaran dimetylu | |
| LT3068869T (lt) | Kompozicijos, skirtos inhibitoriaus prieš faktorių viii susidarymo hemofilinių pacientų organizme slopinimui | |
| ZA201602447B (en) | Improved pharmaceutical compositions of pimobendan | |
| PL3196282T3 (pl) | Kompozycje do czyszczenia | |
| IL240147A0 (en) | Preparations and methods to overcome inhibition of factor a10 | |
| PL3021839T3 (pl) | Kompozycje do leczenia zwłóknienia | |
| ZA201507661B (en) | Racecadotril lipid compositions | |
| EP2968571A4 (en) | BIODEGRADABLE SILICONE BASED COMPOSITIONS FOR THE DELIVERY OF THERAPEUTIC AGENTS | |
| ZA201604163B (en) | Prebiotic oral care compositions containing carboxylic acids | |
| EP3054930A4 (en) | Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine | |
| ZA201604615B (en) | Composition for oral delivery of bioactive agents | |
| IL240763B (en) | The halopyrazoles as thrombin inhibitors | |
| ZA201505650B (en) | New compositions | |
| IL239899A0 (en) | Preparations of thiazomycin compounds | |
| SG11201510578PA (en) | Suppression of itch | |
| EP2961480A4 (en) | GLYCYRRHETINIMIDYL-HYDROXYPROLINE ALKYLESTER AND PROTECTED DERIVATIVES THEREOF | |
| TWI561515B (en) | Metalloenzyme inhibitor compounds | |
| GB201315461D0 (en) | Composition of phosphonates | |
| HUE057170T2 (hu) | Poliészter-kompozíciók alkalmazása |